StimLabs Partners with Vizient to Enhance Patient Care
StimLabs Forms Meaningful Partnership with Vizient
StimLabs, a pioneering regenerative science company, has secured a national contract with Vizient for Regenerative Biologics. This collaboration opens access to over 3,500 hospitals, including an impressive 97% of academic medical centers in the United States.
Benefits of the New Contract
The agreement established with Vizient allows member hospitals to benefit from exclusive pricing and pre-negotiated terms for StimLabs' unique offerings. This includes innovative human placental membrane grafts and the cord-derived particulate device, both essential in advancing medical care.
Leadership Insights on the Collaboration
John Daniel, Founder and CEO of StimLabs, emphasized the significance of this partnership, noting that it significantly enhances their ability to impact patient care directly. He stated, "Our purpose has always been to transform lives through regenerative science. With this agreement, we have significantly expanded our reach and are well positioned to have a larger impact on patient care at the hospital site of service." This sentiment reflects the company’s dedication to improving healthcare through innovative science.
Innovative Products and Pioneering Technologies
Since its inception, StimLabs has remained at the forefront of medical innovation. They were the first to commercialize a full thickness, intact placental membrane allograft utilizing the Clearify technology back in 2016. More recently, in 2024, they launched the first and only FDA 510(k)-cleared umbilical cord-derived medical device known as Corplex P. These groundbreaking advancements showcase their commitment to setting high standards in the industry.
Strategic Growth in the Acute Care Sector
Tom Dion, Executive VP and Chief Commercial Officer at StimLabs, also highlighted the strategic nature of their recent agreement. He expressed that this contract further solidifies their position in the acute care market, enhancing access to 65% of the nation's acute care providers. This movement not only broadens their reach but also enables them to cater to more patients with their diverse portfolio, including their latest innovation.
About StimLabs
Founded in 2015, StimLabs aims to innovate with a transformative purpose in regenerative science. The company is led by industry experts, all dedicated to delivering exceptional patient care while addressing urgent medical needs. Their comprehensive product portfolio target various clinical applications, supported by a robust catalog of intellectual properties. StimLabs is recognized as a dependable partner for both healthcare professionals and patients.
Contact Information
For more information about StimLabs and its offerings, feel free to reach out via the provided media contact information. Reach out to media@stimlabs.com or call (470) 616-0958 for any inquiries.
Frequently Asked Questions
What products does StimLabs provide?
StimLabs offers a unique portfolio including human placental membrane grafts and cord-derived particulate devices.
How does the Vizient partnership benefit hospitals?
It allows hospitals in Vizient's network to access special pricing and pre-negotiated terms for StimLabs products.
What innovations has StimLabs introduced?
StimLabs was the first to introduce an intact placental membrane allograft and later the Corplex P medical device, both pivotal in regenerative medicine.
How is StimLabs impacting patient care?
The partnership with Vizient enables StimLabs to reach more healthcare providers, enhancing patient access to advanced regenerative therapies.
When was StimLabs founded?
StimLabs was established in 2015 and has since focused on transformative innovations in regenerative science.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.